anidulafungin has been researched along with tilorone in 1 studies
| Studies (anidulafungin) | Trials (anidulafungin) | Recent Studies (post-2010) (anidulafungin) | Studies (tilorone) | Trials (tilorone) | Recent Studies (post-2010) (tilorone) |
|---|---|---|---|---|---|
| 568 | 33 | 331 | 369 | 12 | 50 |
| Protein | Taxonomy | anidulafungin (IC50) | tilorone (IC50) |
|---|---|---|---|
| cystic fibrosis transmembrane conductance regulator | Homo sapiens (human) | 30.25 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 4.09 | |
| DNA primase | Mycobacterium tuberculosis CDC1551 | 7.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Byun, SY; Choi, I; Jeon, S; Kim, S; Ko, M; Lee, J; Park, S; Shum, D | 1 |
1 other study(ies) available for anidulafungin and tilorone
| Article | Year |
|---|---|
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
Topics: Animals; Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Coronavirus Infections; COVID-19; Drug Evaluation, Preclinical; Drug Repositioning; Humans; Niclosamide; Pandemics; Pneumonia, Viral; Pregnenediones; SARS-CoV-2; Vero Cells | 2020 |